Navigation Links
Key Pharma Diagnostics and Life Sciences Industry Expertise Added to Board of Directors of Modern Mobility Aids, Inc. (MDRM.OB)
Date:10/13/2011

TORONTO, Oct. 13, 2011 /PRNewswire/ -- Modern Mobility Aids, Inc. (OTC BB: MDRM) (the "Company"), headquartered in Nevada, USA, is adding Darshna Tanna to its Board of Directors. Ms. Tanna's appointment follows the recent announcement of Mr. Ferman Naqvi's, CA, appointment to the Board.  Ms. Tanna's extensive global work experience will help to build the Company's competitive growth in North American and International markets based on her demonstrated track record of generating outstanding business results in diverse cultural and organizational settings worldwide.

Ms. Tanna is currently the Asia-Pacific Regional Director of BioMerieux, a global leader in the field of in-vitro diagnostics. Directly involved in key accounts, new product development as well as management and communications with a network of distributors, she also plays an instrumental role in creating the efficient, highly skilled and motivated team of business managers to build the business in local markets and to grow top-line revenues.

In the past, Ms. Tanna also occupied senior managerial and account positions at Organon Teknika (North America), a biopharmaceutical company engaging in the manufacturing and marketing of prescription medicines primarily in the areas of gynecology, fertility, neuroscience, and anesthesia.  

Commenting on the Company's business evolution, which focuses on the increasing demand from the global pharmaceutical and life sciences industries for innovative delivery and packaging formats, Ms. Tanna remarks, "Developing alternative health care solutions to broaden drug delivery and device packaging options will help to prolong the commercial life of patented medications. For example, moving from a pill to a metered-dose, injectable format or a transdermal patch or an inhaler."  

Mohamed K. Karatella, President and CEO of Modern Mobility Aids, Inc. adds, "Instead of just focusing on commodity manufacturing capacity, such value-added innovation for existing products marketed by larger pharmaceutical firms will sustain our competitive differentiation. We are excited to have Ms. Tanna on board and are certain her vision and experience will accelerate our foray into new markets."

About Modern Mobility Aids, Inc.

Modern Mobility Aids, Inc. was first incorporated under the laws of the State of Nevada on December 19, 2007, under the name of Glider Inc. Its business plan was to sell and distribute products for mobility-challenged individuals. The Company changed its name to Modern Mobility Aids, Inc. on April 22, 2010 with initial plans to distribute products for mobility-challenged individuals. In May of 2011, the business focus of the Company evolved with a rapid expansion strategy in the life sciences and healthcare industry.  A mandate was created to acquire companies within the biopharma sector, targeting innovative research and development as well as scalable manufacturing capacity in three niche market segments: CRAM (Contract Research and Manufacturing for Life Sciences Companies), HEALTHCARE INNOVATION (Novel Drug and Device Delivery Format Packaging) and BIOPHARMA PARTNERSHIPS (Strategic Development and Production Alliances).

Safe Harbor

This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) financing plans; (ii) potential acquisitions, (iii) trends affecting its financial condition or results of operations; (iv) growth strategy and operating strategy. The words "may," "would," "will," "expect, "intend," "estimate," "can," "believe," "potential" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in the Company's filings with the Securities and Exchange Commission.

CONTACT INFO:
Modern Mobility Aids, Inc.
Public Relations and Shareholder Information:   investor@mdrmgroup.com


'/>"/>
SOURCE Modern Mobility Aids, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Express Scripts HealthBridge Pharma & Biotech to Provide Exclusive Specialty Pharmacy Services and Limited Distribution Services for Solesta®
2. PharmAthene Submits Legal Brief in Response to SIGA Technologies Motion for Reargument
3. K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P
4. Study Highlights Emerging Approaches to Medical Education in the Pharmaceutical Sector
5. Avanir Pharmaceuticals to Present Data at the 2011 American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine Annual Conference
6. Amylin Pharmaceuticals to Webcast Third Quarter Results
7. Cumberland Pharmaceuticals Appoints Rick S. Greene Chief Financial Officer
8. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
9. Unity Management Group Receives Large Purchase Order for their AIM Instrumentation Package From Barr Laboratories, Subdivision of TEVA Pharmaceuticals (NASDAQ: TEVA)
10. Endo Pharmaceuticals to Announce Third Quarter 2011 Financial Results on October 27, 2011
11. Alexza Pharmaceuticals to Present at the 18th Annual NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 26, 2016 One of Australia,s ... formation of a new biotechnology company, Noxopharm Limited [ABN 50 608 ... IPO and to list on the ASX. Noxopharm is ... to enter a Phase 1 clinical study later this year. ... one of the biggest problems facing cancer patients - the ability ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... National recruitment ... a life sciences executive with extensive sequencing and genomics experience, as Vice President of ... position, Ms. Hill will be responsible for leading the sales team in the commercialization ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... pluripotent stem (iPS) cells and other difficult to transfect cells, announces its launch ... PluriQ™ G9™ Gene Editing System is a complete system for culturing ...
Breaking Medicine News(10 mins):